ImmuniQ
Personalized Immuno-oncology Treatment
StartupImmuniQ is a startup in the Health Tech & Life Sciences sector, established in 2022. Personalized Immuno-oncology Treatment . ImmuniQ was founded by Moshe Elkabets and Angel Porgador. The company has 1-10 employees. Core technologies: Biologicals, Cells.
The company follows a B2B business model. Product stage: Customer Development.
- StagePre-Funding
- ProductCustomer Development
- ModelB2B
- Employees1-10
- Last RoundUndisclosed
Moshe ElkabetsCo-Founder & CSO
Angel PorgadorCo-founder & CIO
What does ImmuniQ do?
ImmuniQ has developed a method for quantifing the actual and functional tumor response to immunotherapy drugs. The company’s immune checkpoint artificial reporter (IcAR) technology is able to quantify binding and shows the actual surface activity of the patient’s cancer cells, enabling more effective treatment for each patient.
Who founded ImmuniQ?
ImmuniQ was founded in 2022 by Moshe Elkabets (Co-Founder & CSO), Angel Porgador (Co-founder & CIO).
What sector is ImmuniQ in?
ImmuniQ operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.